Lorlatinib is a third-generation ALK TKI used in cases of ALK-positive NSCLC that has progressed with the use of alectinib or ceritinib, or crizotinib and at least another ALK inhibitor. The gene discussed is ALK; the disease is non-small cell lung carcinoma.